

Rushika M Perera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8346886/publications.pdf>

Version: 2024-02-01

39
papers

8,409
citations

147801

31
h-index

302126

39
g-index

43
all docs

43
docs citations

43
times ranked

15682
citing authors

#	ARTICLE	IF	CITATIONS
1	Built to last: lysosome remodeling and repair in health and disease. <i>Trends in Cell Biology</i> , 2022, 32, 597-610.	7.9	24
2	Autophagy in cancer cell remodeling and quality control. <i>Molecular Cell</i> , 2022, 82, 1514-1527.	9.7	31
3	Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-Driven MAPK Pathway Inhibition in Pancreatic Cancer. <i>Cancer Discovery</i> , 2022, 12, 2198-2219.	9.4	32
4	NPC1-mTORC1 Signaling Couples Cholesterol Sensing to Organelle Homeostasis and Is a Targetable Pathway in Niemann-Pick Type C. <i>Developmental Cell</i> , 2021, 56, 260-276.e7.	7.0	101
5	Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth. <i>Nature Cell Biology</i> , 2021, 23, 232-242.	10.3	41
6	Oncogene-regulated release of extracellular vesicles. <i>Developmental Cell</i> , 2021, 56, 1989-2006.e6.	7.0	37
7	Autophagy in major human diseases. <i>EMBO Journal</i> , 2021, 40, e108863.	7.8	615
8	Zooming in on the cell biology of disease. <i>Molecular Biology of the Cell</i> , 2021, 32, ae4.	2.1	1
9	Challenges and opportunities in 2021. <i>Nature Cancer</i> , 2021, 2, 1278-1283.	13.2	1
10	Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. <i>Autophagy</i> , 2020, 16, 1524-1525.	9.1	49
11	Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. <i>Nature</i> , 2020, 581, 100-105.	27.8	628
12	Host Control of Tumor Feeding: Autophagy Holds the Key. <i>Cell Metabolism</i> , 2019, 29, 236-238.	16.2	7
13	Mit/TFE Family of Transcription Factors, Lysosomes, and Cancer. <i>Annual Review of Cancer Biology</i> , 2019, 3, 203-222.	4.5	97
14	Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. <i>ELife</i> , 2019, 8, .	6.0	66
15	Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth. <i>Science</i> , 2017, 356, 1188-1192.	12.6	165
16	Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex. <i>Science</i> , 2017, 355, 1306-1311.	12.6	386
17	The Lysosome as a Regulatory Hub. <i>Annual Review of Cell and Developmental Biology</i> , 2016, 32, 223-253.	9.4	412
18	Beige Adipocyte Maintenance Is Regulated by Autophagy-Induced Mitochondrial Clearance. <i>Cell Metabolism</i> , 2016, 24, 402-419.	16.2	282

#	ARTICLE	IF	CITATIONS
19	YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. <i>Cell Reports</i> , 2015, 10, 1692-1707.	6.4	213
20	Transcriptional control of autophagyâ€“lysosome function drives pancreatic cancer metabolism. <i>Nature</i> , 2015, 524, 361-365.	27.8	624
21	Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. <i>Cancer Discovery</i> , 2015, 5, 1247-1261.	9.4	178
22	Stromal response to Hedgehog signaling restrains pancreatic cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3091-100.	7.1	421
23	CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. <i>Cancer Research</i> , 2014, 74, 3947-3958.	0.9	107
24	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. <i>Nature</i> , 2013, 496, 101-105.	27.8	1,562
25	Ready, Set, Go: The EGF Receptor at the Pancreatic Cancer Starting Line. <i>Cancer Cell</i> , 2012, 22, 281-282.	16.8	20
26	On Oncogenes and Tumor Suppressor Genes in the Mammary Gland. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a013466-a013466.	5.5	8
27	When antioxidants are bad. <i>Nature</i> , 2011, 475, 43-44.	27.8	72
28	The inositol 5-phosphatase SHIP2 regulates endocytic clathrin-coated pit dynamics. <i>Journal of Cell Biology</i> , 2010, 190, 307-315.	5.2	117
29	A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human Cancers. <i>Cancer Research</i> , 2010, 70, 2158-2164.	0.9	72
30	Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17345-17350.	7.1	425
31	A Phosphoinositide Switch Controls the Maturation and Signaling Properties of APPL Endosomes. <i>Cell</i> , 2009, 136, 1110-1121.	28.9	311
32	Structural Basis of Membrane Invagination by F-BAR Domains. <i>Cell</i> , 2008, 132, 807-817.	28.9	509
33	The Efficacy of Epidermal Growth Factor Receptorâ€“Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. <i>Clinical Cancer Research</i> , 2007, 13, 1911-1925.	7.0	64
34	Loss of endocytic clathrin-coated pits upon acute depletion of phosphatidylinositol 4,5-bisphosphate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3793-3798.	7.1	240
35	Internalization, Intracellular Trafficking, Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody. <i>Neoplasia</i> , 2007, 9, 1099-1110.	5.3	67
36	Two synaptojanin 1 isoforms are recruited to clathrin-coated pits at different stages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19332-19337.	7.1	147

#	ARTICLE	IF	CITATIONS
37	Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. <i>Clinical Cancer Research</i> , 2005, 11, 6390-6399.	7.0	103
38	The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. <i>Oncogene</i> , 2004, 23, 6095-6104.	5.9	80
39	Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15871-15876.	7.1	94